Quantcast

Latest Tolerx Inc. Stories

2011-04-05 08:00:00

CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today presented results from preclinical studies with 2F8, a murine analog of TRX518, a first-in-class immunomodulatory agent currently in a Phase 1 clinical study for the treatment of cancer.

2011-03-11 08:02:00

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /PRNewswire/ -- Tolerx, Inc.

2010-08-04 08:08:00

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the appointment of Antonin (Tony) de Fougerolles, Ph.D., as Chief Scientific Officer. Dr.

2010-06-28 06:00:00

CAMBRIDGE, Mass., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes.


Word of the Day
upstander
  • A person who stands up for something, as contrasted to a bystander who remains inactive.
  • One of the upright handlebars on a traditional Inuit sled.
The word 'upstander' in the first sense here is a play on the word 'bystander' and the idea of 'standing up' for something.